TAS-106: preclinical, clinical and beyond

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Fluorinated pyrimidines like 5-Fluorouracil are established chemotherapy agents targeting DNA synthesis in cancer cells.
• These metabolic antagonists are more effective against rapidly proliferating tumors.
• There is a need for novel anticancer drugs that can inhibit both DNA and RNA synthesis.

Purpose of the Study:

• To review the antitumor activity of the novel nucleoside 3 -C-ethynylcytidine (TAS-106).
• To evaluate TAS-106 as a single agent and in combination therapy.
• To focus on preclinical and clinical findings of TAS-106.

Main Methods:

• Molecular design based on biochemical properties of pyrimidine metabolism.
• Development of TAS-106 to inhibit RNA polymerases I, II, and III.
• Review of preclinical and clinical data on TAS-106's efficacy and safety.

Main Results:

• TAS-106 is designed to inhibit RNA synthesis by targeting key RNA polymerases.
• The drug's mechanism of action is effective throughout the cell cycle, excluding M phase.
• Preclinical and clinical studies are investigating its potential as an anticancer therapeutic.

Conclusions:

• TAS-106 represents a new class of anticancer agents with a distinct mechanism of action.
• Its ability to inhibit RNA synthesis offers a potential advantage over traditional DNA-targeting agents.
• Further research and clinical trials are crucial to establish TAS-106's role in cancer treatment.